Program to Provide $100,000 in Support of Communications and Outreach for Patient
Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases
Deadline for Applications is November 11th, 2022
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the fifth annual Cytokinetics Communications Grant Program. The program awards five grants worth $20,000 each to patient advocacy organizations serving the amyotrophic lateral sclerosis (ALS), heart failure or hypertrophic cardiomyopathy (HCM) communities, and is intended to support increased capacity in communications and outreach.
“We initiated this program in 2018 with the goal of helping patient advocacy organizations advance often under-funded marketing and communications efforts,” said Mary Pomerantz, Cytokinetics’ Director of Advocacy. “Over the past five years, our grantees have reached new audiences, built awareness programs and amplified their organizations. We look forward to seeing the continued impact of this program.”
The Cytokinetics Communications Grant Program supports patient advocacy organizations in expanding their reach, awareness and community engagement by providing resources for new or crucial communication or outreach initiatives that would otherwise be challenging to implement. Funding from the Cytokinetics Communications Grant program supports programming or personnel, depending on each organization’s needs. The recipients of the 2022 Cytokinetics Communications Grants were Mended Hearts, the Hypertrophic Cardiomyopathy Association, I AM ALS, the Les Turner ALS Foundation and The ALS Association Northern Ohio Chapter.
Eligible organizations must have nonprofit organization status in the United States and serve the cardiovascular or neuromuscular patient communities in ALS, heart failure or HCM. The deadline to apply is November 11, 2022 and the grant recipients will be announced in January 2023.
Organizations applying for the grant are required to submit a proposal outlining what activities the Cytokinetics Communications Grant Program will support and the potential impact of the funding. Recipients are responsible for providing an outcomes report to Cytokinetics to measure impact at the end of the funding period. For more information on application criteria, and instructions for how to apply, visit https://cytokinetics.com/communicationsgrant/.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is readying for the potential commercialization of omecamtiv mecarbil, its cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is also developing aficamten, a next-generation cardiac myosin inhibitor, currently the subject of SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in non-obstructive HCM in Cohort 4 of the Phase 2 clinical trial, REDWOOD-HCM. Cytokinetics is also developing reldesemtiv, an investigational fast skeletal muscle troponin activator, currently the subject of COURAGE-ALS, a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS). Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact:
Diane Weiser
Senior Vice President, Corporate Communications, Investor Relations
(415) 290-7757
